🚀
Enjoy a 7-Day Free Trial Thru Nov 18, 2024!
✨
Sign Up
Login
Free Sign-up
Login
7-Day Free Trial
Home
Homepage
Membership Levels
About Us
General Discussion
Complete Stock List
The book
Membership Data Coverage
Founder's Message
Free Trial
Referral Program
Partner Program
GuruFocus Podcast
Screeners
GuruFocus Screeners
All-In-One Screener
Strategies Created by Users
Ben Graham Lost Formula
Canadian Faster Growers
CEO Buys
CEO Buys after Price Drop > 20%
Dividend Kings 2023
Dividend Aristocrats 2023
Dividend Growth Portfolio
Dividend Income Portfolio
Fast Growers
Good Companies
Hedge Fund Guru Top 10 Aggregated
High Quality
High Quality Low Capex w ROE ROC min
High Quality & Low Capex
High Yield Insider Buys
Historical High Dividend Yields
International Gurus' Top Holdings
James Montier Short Screen
Margin Decliners
Mega Caps
Peter Lynch & Warren Buffett
Peter Lynch Growth w Lower Valuation
Peter Lynch S&L Traded Below Book
PFCF Screener
Piotroski Score Screener
Predictable Growth Companies
Profitable predictable margin expanders
Stocks Sold w less Cash
The Stalwarts
My Screeners
Create My Screener
Value Screens
Stock Ideas
All-In-One Screener
S&P 500 Map
S&P 500 Bubble
S&P 500 Aggregate
Buffett-Munger Screener
Industry Overview
Undervalued Predictable
Benjamin Graham Net-Net
52-week/3Y/5Y Lows
52-week/3Y/5Y Highs
Magic Formula(Greenblatt)
Dividend Stocks
Peter Lynch Screen
S&P500 Grid
Predictable Companies
Spin Off List
Merger and Acquisition List
Historical Low P/B List
Historical Low P/S List
High Short Interest
Upcoming Special Dividends
Delisted Stocks
Model Portfolios
Performances Overview
Most Broadly Held Portfolio
Most Weighted Portfolio
Buffett-Munger Top 25
GF Score <= 100 Top 25
Top 25 Undervalued Predictable
Top 25 52-week Low Predictable
Top 25 Historical Low P/S
Stock Comparison
Airline Stocks
Artificial Intelligence Stocks
Bank Stocks
Biotech Stocks
Blockchain Stocks
Chinese Stocks
Dividend Stocks
EV Stocks
Growth Stocks
Oil Stocks
Value Stocks
Virtual Reality Stocks
Compare More Stocks…
Gurus
Guru Trades
Latest Guru Picks
Real Time Picks
Guru Portfolio
Score Board
Mutual Funds
Top 10 Holdings
Sector Picks
International Picks
Aggregated Portfolio
Consensus Picks
Guru Bargains
Hot Picks
Download Guru Portfolios
Industry Trends
Geographic Trend
ETFs
Options Holdings
European Shorting
Guru Lists
Complete Guru List
Warren Buffett
Bill Gates
Mohnish Pabrai
Carl Icahn
George Soros
David Tepper
Seth Klarman
Bill Ackman
Joel Greenblatt
Charlie Munger
Michael Price
Julian Robertson
Chuck Akre
David Einhorn
Tom Gayner
My Guru Lists
Insiders
Insider Trading Tracker
Real-Time Insider Picks
CEO Buys/Sells
CFO Buys/Sells
Insider Trends
Insider Cluster
Guru + Insider Double Buys
Triple Buys/Sells
Canadian Insider
Chinese Insider
German Insider
Complete Insider List
Politician Trading Tracker
Real-Time Politician Picks
Complete Politician List
Nancy Pelosi
Mitch Mcconnell
Tommy Tuberville
Josh Gottheimer
Kevin Hern
Thomas R. Carper
Susie Lee
Lois Frankel
Market
US Market Valuation
Buffett Indicator
U.S. Treasury Yield Curve
U.S. Inflation Rate
Presidential Cycle and Stock Market
Shiller P/E
Shiller P/E by Sectors
GF Value for S&P 500 Index
Fed Net Liquidity
Buffett Assets Allocation
Latest IPOs
Global Market Valuation
Global Market Overview
USA
China
Japan
India
Canada
UK
France
Germany
Brazil
Australia
More...
Economic Indicators
Economic Indicators Overview
The Dow Jones Industrial Average (DJIA)
SP 500 Index
Nasdaq Composite Index
Gross Domestic Product (GDP)
Shiller PE
Ratio of Wilshire 5000 over GNP
Civilian Unemployment Rate
Russell 2000 Index
CBOE Volatility Index (VIX)
Total Nonfarm Payrolls: All Employees
More...
Sector & Industry Performance
Global Industry Overview
USA
Asia
Europe
Canada
UK/Ireland
Oceania
Latin America
Africa
India/Pakistan
Articles
Articles
Editors' Picks
Stock Market News
Q&A with Gurus
Guru Stock Picks
Insider Transaction
Earning Reports
Podcast
Earnings Call Transcripts
Software Stock News
Biotechnology Stock News
Hardware Stock News
Banks Stock News
Metals & Mining Stock News
Drug Manufacturers Stock News
Instant Alerts
All Articles
Submit Articles
Submit Article Online
Contributor Guidelines
Tools
Model Portfolios
All-In-One Screener
Data Batch Download
Guru Portfolio Download
Insider Data Download
Excel Add-In
Google Sheets Add-On
API
Manual of Stocks
DCF Calculator
WACC Calculator
Interactive Chart
Maps
Fund Letters Archive
Stock Comparison Table
Mobile App
Discussion Board
GuruAI
Financial Calendar
Embed Widgets
Stock Market Holidays
Discussion
All Topics
General Discussions
Investment Ideas
Strategies
Article Comments
Books
Feedback
Data
Pricing
Tutorials
Tutorials
Financial Glossary
FAQ
Change Log
Contact Us
Support
Chat Support
Create a ticket
Book Demo
User Engagement Meeting
469-248-6885
Status
Take Survey
Subscribe
Free Trial
Group Subscription
Refer a Friend and Earn One Month of Free Membership
GURUFOCUS.COM
STOCK LIST
Healthcare
Biotechnology
Alnylam Pharmaceuticals Inc (NAS:ALNY)
Transcripts
Alnylam Pharmaceuticals Inc (NAS:ALNY)
$ 282.085
4.655 (1.68%)
Market Cap: 36.38 Bil
Enterprise Value: 34.33 Bil
PE Ratio: 0
PB Ratio: 1,128.34
GF Score: 78/100
0
Summary
30-Y Financials
Forecast
DCF
Dividend
Guru Trades
Insider
Interactive Chart
Filings
Transcripts
News
Compare
Stock PDF
Ownership
Operating
Checklist
Vote
Definitions
Alnylam Pharmaceuticals Inc (ALNY) Transcripts
Q3 2024 Alnylam Pharmaceuticals Inc Earnings Call Transcript
Oct 31, 2024
$266.59
(-5.29%)
Earnings
Show Key Points
Q2 2024 Alnylam Pharmaceuticals Inc Earnings Call Transcript
Aug 01, 2024
$268.61
(+13.12%)
Earnings
Show Key Points
Q1 2024 Alnylam Pharmaceuticals Inc Earnings Call Transcript
May 02, 2024
$150.31
(+0.23%)
Earnings
Show Key Points
Q4 2023 Alnylam Pharmaceuticals Inc Earnings Call Transcript
Feb 15, 2024
$147.43
(-10.19%)
Earnings
Alnylam Pharmaceuticals Inc at JPMorgan Healthcare Conference Transcript
Jan 08, 2024
Alnylam Pharmaceuticals Inc R&D Day Transcript
Dec 13, 2023
Alnylam Pharmaceuticals Inc at Piper Sandler Healthcare Conference Transcript
Nov 29, 2023
Alnylam Pharmaceuticals Inc at Stifel Healthcare Conference Transcript
Nov 14, 2023
Alnylam Pharmaceuticals Inc at Jefferies London Healthcare Conference Transcript
Nov 14, 2023
Q3 2023 Alnylam Pharmaceuticals Inc Earnings Call Transcript
Nov 02, 2023
$161.53
(+2.89%)
Earnings
Alnylam Pharmaceuticals Inc To Host Investor Call Transcript
Oct 09, 2023
Alnylam Pharmaceuticals Inc at Canaccord Genuity Growth Conference Transcript
Aug 10, 2023
Q2 2023 Alnylam Pharmaceuticals Inc Earnings Call Transcript
Aug 03, 2023
$190.1
(+1.65%)
Earnings
Alnylam Pharmaceuticals Inc to Discuss Collaboration with Roche Transcript
Jul 24, 2023
Alnylam Pharmaceuticals Inc at Goldman Sachs Healthcare Conference Transcript
Jun 12, 2023
Alnylam Pharmaceuticals Inc at Bank of America Global Healthcare Conference Transcript
May 10, 2023
Q1 2023 Alnylam Pharmaceuticals Inc Earnings Call Transcript
May 04, 2023
$205.39
(+2.95%)
Earnings
Alnylam Pharmaceuticals Inc ALN-APP Call Transcript
Apr 26, 2023
Alnylam Pharmaceuticals Inc at Ginkgo Bioworks Ferment Conference Transcript
Apr 19, 2023
Alnylam Pharmaceuticals Inc at Stifel CNS Days (Virtual) Transcript
Mar 29, 2023
Alnylam Pharmaceuticals Inc at Barclays Global Healthcare Conference Transcript
Mar 16, 2023
Alnylam Pharmaceuticals Inc at Oppenheimer Healthcare Conference (Virtual) Transcript
Mar 15, 2023
Alnylam Pharmaceuticals Inc at Cowen Health Care Conference Transcript
Mar 08, 2023
Q4 2022 Alnylam Pharmaceuticals Inc Earnings Call Transcript
Feb 23, 2023
$196.24
(-2.42%)
Earnings
Alnylam Pharmaceuticals Inc at JPMorgan Healthcare Conference Transcript
Jan 09, 2023
Alnylam Pharmaceuticals Inc R&D Day Transcript
Dec 15, 2022
Alnylam Pharmaceuticals Inc at Piper Sandler Healthcare Conference Transcript
Nov 30, 2022
Alnylam Pharmaceuticals Inc at Evercore ISI HealthCONx Conference (Virtual) Transcript
Nov 29, 2022
Alnylam Pharmaceuticals Inc at Stifel Healthcare Conference Transcript
Nov 16, 2022
Alnylam Pharmaceuticals Inc at Jefferies London Healthcare Conference Transcript
Nov 16, 2022
Alnylam Pharmaceuticals Inc “RNAi Roundtable” Webcast Series: CNS Delivery and ALN-APP, in Development for the Treatment of Alzheimer's Disease and Cerebral Amyloid Angiopathy Transcript
Nov 01, 2022
Q3 2022 Alnylam Pharmaceuticals Inc Earnings Call Transcript
Oct 27, 2022
$194
(-3.49%)
Earnings
Alnylam Pharmaceuticals Inc “RNAi Roundtable” Webcast Series: Alnylam Engine for Sustainable Innovation: Leadership in RNAi Platform and Human Genetics Transcript
Oct 21, 2022
Alnylam Pharmaceuticals Inc to Discuss APOLLO-B Results at HFSA Scientific Meeting Transcript
Oct 01, 2022
Alnylam Pharmaceuticals Inc “RNAi Roundtable” Webcast Series: Cemdisiran, in Development for the Treatment of IgA Nephropathy (IgAN) and Other Complement-Mediated Diseases Transcript
Sep 27, 2022
Alnylam Pharmaceuticals Inc at Morgan Stanley Global Healthcare Conference Transcript
Sep 13, 2022
Alnylam Pharmaceuticals Inc to Discuss APOLLO-B Results - Conference Call Transcript
Sep 08, 2022
Alnylam Pharmaceuticals Inc to Discuss APOLLO-B Topline Results Transcript
Aug 03, 2022
Q2 2022 Alnylam Pharmaceuticals Inc Earnings Call Transcript
Jul 28, 2022
$143.52
(+1.09%)
Earnings
Alnylam Pharmaceuticals Inc to Discuss FDA Approval of AMVUTTRA (Vutrisiran) Transcript
Jun 14, 2022
Alnylam Pharmaceuticals Inc at Goldman Sachs Global Healthcare Conference Transcript
Jun 13, 2022
Alnylam Pharmaceuticals Inc at Jefferies Healthcare Conference Transcript
Jun 09, 2022
Alnylam Pharmaceuticals Inc at UBS Global Healthcare Conference Transcript
May 25, 2022
Alnylam Pharmaceuticals Inc at H C Wainwright Global Investment Conference (Virtual) Transcript
May 24, 2022
Alnylam Pharmaceuticals Inc at Bank of America Healthcare Conference Transcript
May 11, 2022
Q1 2022 Alnylam Pharmaceuticals Inc Earnings Call Transcript
Apr 28, 2022
$143.16
(-7.59%)
Earnings
Alnylam Pharmaceuticals Inc at Stifel CNS Days (Virtual) Transcript
Mar 28, 2022
Alnylam Pharmaceuticals Inc at Barclays Global Healthcare Conference Transcript
Mar 15, 2022
Alnylam Pharmaceuticals Inc at Cowen Health Care Conference (Virtual) Transcript
Mar 08, 2022
Alnylam Pharmaceuticals Inc at SVB Leerink Global Healthcare (Virtual) Transcript
Feb 17, 2022
Q4 2021 Alnylam Pharmaceuticals Inc Earnings Call Transcript
Feb 10, 2022
$150.86
(-0.36%)
Earnings
Alnylam Pharmaceuticals Inc to Present HELIOS-A 18-Month Results - Conference Call Transcript
Jan 21, 2022
Alnylam Pharmaceuticals Inc at JPMorgan Healthcare Conference (Virtual) Transcript
Jan 10, 2022
Alnylam Pharmaceuticals Inc at Piper Sandler Healthcare Conference (Virtual) Transcript
Dec 02, 2021
Alnylam Pharmaceuticals Inc at Evercore ISI HealthCONx Virtual Conference Transcript
Nov 30, 2021
Alnylam Pharmaceuticals Inc Virtual R&D Day Transcript
Nov 19, 2021
Q3 2021 Alnylam Pharmaceuticals Inc Earnings Call Transcript
Oct 28, 2021
$162.14
(-15.18%)
Earnings
Alnylam Pharmaceuticals Inc at Chardan Genetic Medicines Conference (Virtual) Transcript
Oct 05, 2021
Alnylam Pharmaceuticals Inc “RNAi Roundtable” Webcast Series: CNS & Extrahepatic RNAi Pipeline Programs Transcript
Oct 01, 2021
Alnylam Pharmaceuticals Inc at Cantor Fitzgerald Global Healthcare Conference (Virtual) Transcript
Sep 28, 2021
Alnylam Pharmaceuticals Inc “RNAi Roundtable” Webcast Series: Liver-Directed RNAi Pipeline Programs Transcript
Sep 20, 2021
Alnylam Pharmaceuticals Inc at Bank of America Global Healthcare Conference (Virtual) Transcript
Sep 16, 2021
Alnylam Pharmaceuticals Inc at H C Wainwright Global Investment Conference (Virtual) Transcript
Sep 13, 2021
Alnylam Pharmaceuticals Inc at Morgan Stanley Global Healthcare Conference (Virtual) Transcript
Sep 09, 2021
Alnylam Pharmaceuticals Inc “RNAi Roundtable” Webcast Series: Lumasiran, for the Treatment of Primary Hyperoxaluria Type 1 Transcript
Aug 19, 2021
Alnylam Pharmaceuticals Inc “RNAi Roundtable” Webcast Series: Givosiran, for the Treatment of Acute Hepatic Porphyria Transcript
Aug 04, 2021
Q2 2021 Alnylam Pharmaceuticals Inc Earnings Call Transcript
Aug 03, 2021
$178.81
(+0.48%)
Earnings
Alnylam Pharmaceuticals Inc "RNAi Roundtable" Webcast Series: Patisiran & Vutrisiran, in Development for the Treatment of ATTR Amyloidosis Transcript
Jul 16, 2021
Alnylam Pharmaceuticals Inc "RNAi Roundtable” Webcast Series: ALN-AGT, in Development for the Treatment of Hypertension Transcript
Jun 30, 2021
Alnylam Pharmaceuticals Inc at Nasdaq Investor Conference (Virtual) Transcript
Jun 15, 2021
Alnylam Pharmaceuticals Inc at Goldman Sachs Global Healthcare Conference (Virtual) Transcript
Jun 08, 2021
Alnylam Pharmaceuticals Inc at Sanford C Bernstein Strategic Decisions Conference (Virtual) Transcript
Jun 03, 2021
Alnylam Pharmaceuticals Inc at Jefferies Healthcare Conference (Virtual) Transcript
Jun 01, 2021
Alnylam Pharmaceuticals Inc at UBS Global Healthcare Virtual Conference Transcript
May 25, 2021
Alnylam Pharmaceuticals Inc Annual Shareholders Meeting Transcript
May 18, 2021
Alnylam Pharmaceuticals Inc at Bank of America Global Research Healthcare Conference (Virtual) Transcript
May 11, 2021
Q1 2021 Alnylam Pharmaceuticals Inc Earnings Call Transcript
Apr 29, 2021
$139.69
(-2.68%)
Earnings
Alnylam Pharmaceuticals Inc to Discuss Full 9-Month Results from the HELIOS-A Phase 3 Study of Vutrisiran - Corporate Call Transcript
Apr 19, 2021
Alnylam Pharmaceuticals Inc at Needham Healthcare Conference (Virtual) Transcript
Apr 13, 2021
Alnylam Pharmaceuticals Inc at Stifel CNS Day Transcript
Apr 01, 2021
Alnylam Pharmaceuticals Inc at Barclays Global Healthcare Conference (Virtual) Transcript
Mar 10, 2021
Alnylam Pharmaceuticals Inc at H C Wainwright Global Life Sciences Conference (Virtual) Transcript
Mar 09, 2021
Alnylam Pharmaceuticals Inc at Cowen Healthcare Conference (Virtual) Transcript
Mar 01, 2021
Alnylam Pharmaceuticals Inc at SVB Leerink Global Healthcare Conference (Virtual) Transcript
Feb 25, 2021
Q4 2020 Alnylam Pharmaceuticals Inc Earnings Call Transcript
Feb 11, 2021
$165.38
(+0.74%)
Earnings
Alnylam Pharmaceuticals Inc at JPMorgan Healthcare Conference (Virtual) Transcript
Jan 11, 2021
Alnylam Pharmaceuticals Inc to Discuss Topline HELIOS-A Phase 3 Results of Vutrisiran - Conference Call Transcript
Jan 07, 2021
Alnylam Pharmaceuticals Inc R&D Day 2020 (Event 2) Transcript
Dec 16, 2020
Alnylam Pharmaceuticals Inc R&D Day 2020 (Event 1) Transcript
Dec 15, 2020
Alnylam Pharmaceuticals Inc at Nasdaq Virtual Investor Conference Transcript
Dec 04, 2020
Alnylam Pharmaceuticals Inc to Discuss FDA Approval of OXLUMO (Lumasiran) Conference Call Transcript
Nov 24, 2020
Alnylam Pharmaceuticals Inc at Stifel Virtual Healthcare Conference Transcript
Nov 16, 2020
Alnylam Pharmaceuticals Inc at Credit Suisse Healthcare Conference (Virtual) Transcript
Nov 09, 2020
Q3 2020 Alnylam Pharmaceuticals Inc Earnings Call Transcript
Nov 05, 2020
$137.86
(-1.17%)
Earnings
Alnylam Pharmaceuticals Inc at H C Wainwright Hepatitis B Virus (HBV) Mini-Conference (Virtual) Transcript
Oct 20, 2020
Alnylam Pharmaceuticals Inc at Chardan Genetic Medicines Conference (Virtual) Transcript
Oct 05, 2020
Alnylam Pharmaceuticals Inc at Bank of America Merrill Lynch Global Healthcare Conference (Virtual) Transcript
Sep 17, 2020
Alnylam Pharmaceuticals Inc at Cantor Fitzgerald Global Healthcare Conference (Virtual) Transcript
Sep 16, 2020
Alnylam Pharmaceuticals Inc at Morgan Stanley Global Healthcare Conference (Virtual) Transcript
Sep 15, 2020
Alnylam Pharmaceuticals Inc at Citi BioPharma Conference (Virtual) Transcript
Sep 10, 2020
BridgeBio Pharma Inc at Citi BioPharma Conference (Virtual)- Panel: TTR Amyloidosis Transcript
Sep 09, 2020
Alnylam Pharmaceuticals Inc “RNAi Roundtable” Webcast Series: Patisiran & Vutrisiran, in Development for the Treatment of Transthyretin-Mediated Amyloidosis Transcript
Sep 03, 2020
Alnylam Pharmaceuticals Inc “RNAi Roundtable” Webcast Series: Lumasiran, in Development for the Treatment of Primary Hyperoxaluria Type I Transcript
Aug 10, 2020
Q2 2020 Alnylam Pharmaceuticals Inc Earnings Call Transcript
Aug 06, 2020
$144.12
(-4.20%)
Earnings
Alnylam Pharmaceuticals Inc “RNAi Roundtable” Webcast Series: Early Stage RNAi Therapeutics Pipeline Transcript
Jul 17, 2020
Alnylam Pharmaceuticals Inc at Bank of America Merrill Lynch Napa Healthcare Conference (Virtual) Transcript
Jun 24, 2020
Alnylam Pharmaceuticals Inc "RNAi Roundtable” Webcast Series: ALN-AGT, in Development for the Treatment of Hypertension Transcript
Jun 23, 2020
Alnylam Pharmaceuticals Inc at Goldman Sachs Global Healthcare Conference (Virtual) Transcript
Jun 11, 2020
Alnylam Pharmaceuticals Inc to Discuss Full Results from ILLUMINATE-A Phase 3 Study of Lumasiran at ERA-EDTA International Congress Transcript
Jun 07, 2020
Alnylam Pharmaceuticals Inc at Jefferies Healthcare Conference (Virtual) Transcript
Jun 02, 2020
Alnylam Pharmaceuticals Inc at UBS Global Healthcare Conference (Virtual) Transcript
May 20, 2020
Alnylam Pharmaceuticals Inc at Bank of America Merrill Lynch Healthcare Conference (Virtual) Transcript
May 14, 2020
Alnylam Pharmaceuticals Inc Annual Shareholders Meeting Transcript
May 06, 2020
Q1 2020 Alnylam Pharmaceuticals Inc Earnings Call Transcript
May 06, 2020
$145.27
(+2.86%)
Earnings
Alnylam Pharmaceuticals Inc at Needham Healthcare Conference Transcript
Apr 14, 2020
Alnylam Pharmaceuticals Inc Conference Call to Discuss Strategic Financing Collaboration with Blackstone Transcript
Apr 13, 2020
Alnylam Pharmaceuticals Inc at Barclays Global Healthcare Conference Transcript
Mar 10, 2020
Alnylam Pharmaceuticals Inc at Cowen HealthCare Conference Transcript
Mar 03, 2020
Alnylam Pharmaceuticals Inc at Leerink Global Healthcare Conference Transcript
Feb 27, 2020
Q4 2019 Alnylam Pharmaceuticals Inc Earnings Call Transcript
Feb 06, 2020
$121.96
(+0.30%)
Earnings
Alnylam Pharmaceuticals Inc at JPMorgan Healthcare Conference Transcript
Jan 13, 2020
Alnylam Pharmaceuticals Inc to Discuss Topline Results from ILLUMINATE-A Phase 3 Study of Lumasiran Conference Call Transcript
Dec 17, 2019
Alnylam Pharmaceuticals Inc at Piper Jaffray Healthcare Conference Transcript
Dec 05, 2019
Alnylam Pharmaceuticals Inc at Evercore HealthCONx Conference Transcript
Dec 04, 2019
Alnylam Pharmaceuticals Inc R&D Day 2019 Transcript
Nov 22, 2019
Alnylam Pharmaceuticals Inc Conference Call to Discuss FDA Approval of GIVLAARI (Givosiran) Transcript
Nov 20, 2019
Alnylam Pharmaceuticals Inc at Stifel Healthcare Conference Transcript
Nov 19, 2019
Q3 2019 Alnylam Pharmaceuticals Inc Earnings Call Transcript
Oct 31, 2019
$86.74
(-0.61%)
Earnings
Alnylam Pharmaceuticals Inc “RNAi Roundtable” Webcast Series: Lumasiran, in Development for the Treatment of Primary Hyperoxaluria Type 1 Transcript
Oct 10, 2019
Alnylam Pharmaceuticals Inc “RNAi Roundtable” Webcast Series: Givosiran, in Development for the Treatment of Acute Hepatic Porphyria Transcript
Oct 07, 2019
Alnylam Pharmaceuticals Inc at Cantor Fitzgerald Global Healthcare Conference Transcript
Oct 03, 2019
Alnylam Pharmaceuticals Inc "RNAi Roundtable" Webcast Series: Patisiran & Vutrisiran, for the Treatment of Transthyretin-Mediated Amyloidosis Transcript
Sep 16, 2019
Alnylam Pharmaceuticals Inc at Morgan Stanley Healthcare Conference Transcript
Sep 09, 2019
Q2 2019 Alnylam Pharmaceuticals Inc Earnings Call Transcript
Aug 06, 2019
$74.38
(+4.16%)
Earnings
Alnylam Pharmaceuticals Inc at Goldman Sachs Global Healthcare Conference Transcript
Jun 12, 2019
Alnylam Pharmaceuticals Inc at Jefferies Healthcare Conference Transcript
Jun 07, 2019
Alnylam Pharmaceuticals Inc at Bank of America Merrill Lynch Health Care Conference Transcript
May 16, 2019
Q1 2019 Alnylam Pharmaceuticals Inc Earnings Call Transcript
May 01, 2019
$83.03
(-7.06%)
Earnings
Alnylam Pharmaceuticals Inc Annual Shareholders Meeting Transcript
Apr 25, 2019
Alnylam Pharmaceuticals Inc to Present Givosiran Phase 3 Data at the European Association for the Study of the Liver (EASL) International Liver Congress Conference Call Transcript
Apr 13, 2019
Alnylam Pharmaceuticals Inc to Discuss Regeneron Collaboration - Call Transcript
Apr 08, 2019
Alnylam Pharmaceuticals Inc at Cowen Health Care Conference Transcript
Mar 13, 2019
Alnylam Pharmaceuticals Inc to Discuss Topline Results from ENVISION Phase 3 Study of Givosiran Conference Call Transcript
Mar 06, 2019
Alnylam Pharmaceuticals Inc at Leerink Partners Global Healthcare Conference Transcript
Feb 27, 2019
Alnylam Pharmaceuticals Inc at Biotechnology Industry Organization (BIO) CEO & Investor Conference Transcript
Feb 11, 2019
Q4 2018 Alnylam Pharmaceuticals Inc Earnings Call Transcript
Feb 07, 2019
$80.8
(-1.17%)
Earnings
1